The Omeros OMS721 aHus drug will compete with Alexion’s Soliris, reportedly the “world’s most expensive drug,” costing up to $700,000 per year. http://news.nationalpost.com/health/worlds-most-expensive-drug-prescription-that-costs-up-to-700000-per-year-too-expensive-canada-says Even if Omeros substantially discounts OMS721 relative to Soliris, potential revenues of a few hundred million seem plausible. Plus, the FDA granted Fast Track designation to OMS721. So today’s price jump may not be unreasonable. (FD: I’m a long-time holder of OMER.) Good health & good vibes, Bulba
Special Note: Do not have a scientific background. Sadly recall passing up meeting founder and former CEO (as I was prepping for cross country move) pre-IPO funding of ALXN thru a good friend in early '90s that took it public.